Overview

COVID-19 Huashi Baidu Formula Clinical Study

Status:
Not yet recruiting
Trial end date:
2024-05-01
Target enrollment:
Participant gender:
Summary
Combined with the regional and population characteristics of Asia and Africa, Huashi Baidu Granule was used to intervene in mild and ordinary patients with COVID-19, evaluate its efficacy and safety, and clarify its characteristics of action.
Phase:
N/A
Details
Lead Sponsor:
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Collaborators:
Beijing YouAn Hospital
Kamuzu University of Health Sciences
Kossamak Hospital